K-877

Summary

K-877 (CHEMBL3545412) is a phase-3 clinical-stage unknown; indicated across 6 conditions including hypertriglyceridemia and hyperlipidemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 6 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545412
Name	K-877
Type	Unknown
Max phase	3

Also known as: K-877

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertriglyceridemia	3	MONDO:0005347	EFO:0004211
hyperlipidemia	3	MONDO:0021187	MONDO:0021187
metabolic dysfunction-associated steatotic liver disease	2	MONDO:0013209	EFO:0003095
metabolic dysfunction-associated steatohepatitis	2	MONDO:0007027	EFO:1001249

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE1	9
PHASE3	4
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03001817	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
NCT03011450	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
NCT03071692	PHASE3	TERMINATED	Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
NCT05923281	PHASE3	COMPLETED	A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance
NCT03350165	PHASE2	COMPLETED	A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
NCT02273986	PHASE1	COMPLETED	Drug-Drug Interaction Study in Health Adult Volunteers
NCT02275962	PHASE1	COMPLETED	Drug-Drug Interaction Study in Healthy Adult Volunteers
NCT02275975	PHASE1	COMPLETED	Drug-Drug Interaction Study in Healthy Adult Volunteers
NCT02275988	PHASE1	COMPLETED	Drug-Drug Interaction Study in Healthy Adult Volunteers
NCT02276001	PHASE1	COMPLETED	Drug-Drug Interaction Study in Healthy Adult Volunteers
NCT02719431	PHASE1	COMPLETED	Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers
NCT02922465	PHASE1	COMPLETED	Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers
NCT04237597	PHASE1	COMPLETED	Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers
NCT04742218	PHASE1	COMPLETED	Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).